A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease by Gjerum, Le et al.
u n i ve r s i t y  o f  co pe n h ag e n  
A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate
dementia with Lewy bodies and Alzheimer's disease
Gjerum, Le; Frederiksen, Kristian Steen; Henriksen, Otto Mølby; Law, Ian; Anderberg, Lasse;
Andersen, Birgitte Bo; Bjerregaard, Eva; Hejl, Anne Mette; Høgh, Peter; Hasselbalch, Steen
Gregers
Published in:
Journal of the Neurological Sciences
DOI:
10.1016/j.jns.2019.116645
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Gjerum, L., Frederiksen, K. S., Henriksen, O. M., Law, I., Anderberg, L., Andersen, B. B., ... Hasselbalch, S. G.
(2020). A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy
bodies and Alzheimer's disease. Journal of the Neurological Sciences, 410, [116645].
https://doi.org/10.1016/j.jns.2019.116645
Download date: 23. Jun. 2020
Contents lists available at ScienceDirect
Journal of the Neurological Sciences
journal homepage: www.elsevier.com/locate/jns
A visual rating scale for cingulate island sign on 18F-FDG-PET to
differentiate dementia with Lewy bodies and Alzheimer's disease
Le Gjeruma,⁎, Kristian Steen Frederiksena, Otto Mølby Henriksenb, Ian Lawb, Lasse Anderbergb,
Birgitte Bo Andersena, Eva Bjerregaarda, Anne-Mette Hejlc, Peter Høghd,e,
Steen Gregers Hasselbalcha
a Department of Neurology, Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
bDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
c Department of Neurology, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark
d Regional Dementia Research Center, Department of Neurology, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark
e Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark
A R T I C L E I N F O
Keywords:
Cingulate island sign
FDG-PET
Dementia with Lewy bodies
Alzheimer's disease
Dual pathology
Visual rating scale
A B S T R A C T
Valid diagnosis of dementia with Lewy bodies (DLB) is essential to establish appropriate treatment and care.
However, the diagnostic accuracy is complicated by clinical and pathological overlap with Alzheimer's disease
(AD). Cingulate island sign (CIS), defined as sparing of posterior cingulate cortex (PCC) relative to precuneus and
cuneus on 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET), is included in the revised
diagnostic DLB criteria. There are no guidelines for the visual grading of CIS, although visual rating is a fast-
applicable method in a clinical setting.
The objective was to develop a robust visual CIS scale and evaluate the performance in differentiating DLB
with and without amyloid beta pathology (Aβ+/−), and AD.
18F-FDG-PET scans from 35 DLB patients, 36 AD patients, and 23 healthy controls were rated according to a
visual CIS scale based on specific reading criteria. The visual CIS scale was validated against a quantitative CIS
ratio derived from a region of interest analysis of PCC, precuneus, and cuneus.
DLB patients had a significantly higher visual CIS score compared to AD patients, and controls.
A cut-off visual CIS score of 4 significantly differentiated DLB Aβ− patients from DLB Aβ+ patients.
In conclusion, the visual CIS scale is clinically useful to differentiate DLB from AD. The degree of CIS may be
related to Aβ pathology in DLB patients.
1. Introduction
Dementia with Lewy bodies (DLB), which is pathologically char-
acterized by accumulation of Lewy bodies (LB), is the second most
common cause of neurodegenerative dementia after Alzheimer's disease
(AD) [24]. Early and accurate diagnosis of DLB is essential to enable
appropriate treatment and care, in addition to identify and manage
clinical features including motor and psychiatric symptoms, severe
autonomic dysfunction and hazardous antipsychotic sensitivity [26]. A
valid diagnosis is also central for predicting the prognosis of the disease
and planning clinical trials, but the diagnostic process may be compli-
cated by substantial overlap in clinical and neuropsychological features
between AD and DLB [23]. Furthermore, the frequent occurrence of
pathological heterogeneity in DLB patients, particularly coexisting AD
pathology, i.e. amyloid beta (Aβ) plaques and tau tangles, can con-
tribute to diverse clinical presentations [33,34]. Aβ pathology in pa-
tients with DLB has been associated with faster cognitive decline and
shorter survival compared to the DLB patients with pure LB pathology
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[6,16]. These findings underline the clinical relevance of identifying
coexisting Aβ pathology in DLB patients.
Functional neuroimaging has become a commonly used supplement
to the clinical diagnosis of dementia [36], and has also been introduced
in the diagnostic criteria for both DLB and AD [26,27]. Several studies
have demonstrated occipital hypometabolism as a supportive feature to
distinguish DLB patients from AD patients on positron emission tomo-
graphy (PET) imaging using 18F-fluoro-deoxy-glucose as tracer (18F-
FDG-PET) [1,18,19,29].
Cingulate island sign (CIS) is another identified feature on 18F-FDG-
PET to support the diagnosis of DLB, and has been found to be more
specific than occipital hypometabolism for DLB [21]. CIS is defined as
preserved metabolism of the posterior cingulate cortex (PCC) relative to
reduced metabolism in the precuneus and the cuneus, and is included in
the updated diagnostic DLB criteria [26]. The CIS ratio, defined as the
measure of FDG uptake in the PCC divided by the sum of the uptake in
the precuneus and the cuneus, is higher in DLB patients compared to AD
patients as demonstrated by a semi-quantitative method
[11,15,19,21,31]. A quantitative method can be time consuming, re-
quires standardized acquisition and analysis of both the 18F-FDG-PET
and the structural scan, i.e. either computed tomography (CT) or
magnetic resonance imaging (MRI), and the specific software may only
be accessible in expert centres. Of interest, a dichotomous visual in-
terpretation of CIS (present or absent) had a higher diagnostic accuracy
compared to the quantitative CIS ratio in distinguishing DLB patients
from AD patients [21]. However, there are no established visual criteria
for the degree of CIS, even though visual rating of other imaging bio-
markers and modalities are commonly used and has proven to be a fast,
reliable and reproducible method in clinical practice [14,36,37]. The
application of a standardized method to classify and interpret the pre-
sence of CIS may enhance the utilization of relevant diagnostic in-
formation, along with improving the diagnostic accuracy of DLB. Fur-
thermore, a visual rating scale can easily be implemented into the
clinical practice across centres and assist the less experienced nuclear
medicine physicians.
The objectives of this study were (1) to develop a robust visual
rating scale for the presence of CIS on 18F-FDG-PET (the visual CIS
scale); (2) to evaluate the reproducibility and the accuracy of the visual
CIS scale to differentiate DLB patients and AD patients; (3) to compare
the performance of the visual CIS scale to a quantitative method for CIS
(the quantitative CIS ratio) and 18F-FDG-PET visual features of occi-
pital involvement and forced diagnosis; (4) to examine whether coex-
isting Aβ pathology influenced the presence of CIS for the DLB patients.
2. Materials and methods
2.1. AD and DLB study population
The study population consisted of retrospectively identified patients
with a clinical diagnosis of DLB according to the DLB criteria [25] and
AD according to the AD criteria [27] diagnosed from 2011 to 2017 at
four Danish memory clinics in the greater Copenhagen area (Rig-
shospitalet, Glostrup Hospital, Bispebjerg Hospital, and Roskilde Hos-
pital).
The dementia diagnoses were confirmed according to the estab-
lished clinical criteria by an experienced dementia specialist (SGH, AH,
or PH) based on patient files from baseline to the most recent clinical
follow up and all available examination results (except the 18F-FDG-
PET findings).
All eligible patients had a structural scan, i.e. either CT or MRI, a
18F-FDG-PET scan, and determination of the brain Aβ status, i.e. either
measurement of Aβ 1–42 (Aβ42) in the cerebrospinal fluid (CSF) or PET
imaging using the ligand 11C-Pittsburgh compound B (11C-PiB-PET).
For patients with DLB an abnormal 123I-2β-carbomethoxy-3β-(4-
iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) dopamine
transporter single photon emission computed tomography (123I-FP-
CIT-DAT-SPECT) scan was also required.
Thirty-seven patients with a clinical diagnosis of DLB and 37 pa-
tients with a clinical diagnosis of AD matched on age, sex, and MMSE
were included.
The retrospective use of clinical data was approved by the Danish
Patient Safety Authority (no. 3-3013-2703/1).
2.2. Healthy controls
A group of 23 healthy elderly controls aged over 60 years with
normal MRI and 18F-FDG-PET results, and normal neuropsychology
scores from the Memory Clinic at Rigshospitalet was also included. The
controls consisted of 18 healthy research volunteers and five subjects
with subjective cognitive decline in whom dementia and neurodegen-
erative disease had been ruled out. All controls had no evidence of brain
amyloid accumulation, i.e. normal concentration of Aβ42 in CSF, ex-
cept three of the healthy research volunteers who did not undergo as-
sessment of brain amyloid.
All healthy research volunteers gave a written informed consent,
and the inclusion was approved by the Danish National Committee on
Health Research (no. H-1-2014-126).
2.3. Clinical examinations
All patients and controls underwent a standardized diagnostic de-
mentia assessment including medical history, physical and neurological
examinations, cognitive testing (i.e. Mini mental state examination
(MMSE) and Addenbrooke's cognitive examination), routine blood
screening, and a structural scan, i.e. either CT or MRI.
The dementia patients were followed up longitudinally as part of the
standard clinical routine, and 93% of the patients were followed for at
least 12 months.
2.4. Assessment of brain amyloid
The brain amyloid accumulation was determined by either Aβ42 in
CSF (n= 76), 11C-PiB-PET imaging (n= 5), or both (n= 10). If the Aβ
biomarkers were incongruent (n = 5) the result of the 11C-PiB-PET
image determined the Aβ status.
The CSF was collected by lumbar puncture in polypropylene tubes,
and Aβ42 was analysed with the enzyme-linked immunosorbent assay
(ELISA) using the commercially available kit (Innotest, Fujirebio,
Europe, Ghent, Belgium). An abnormal Aβ42 (< 550 pg/mL) was in-
dicated as Aβ+, whereas a normal Aβ42 was indicated as Aβ− [40].
2.5. Imaging
Imaging was performed over a seven-year period at different hos-
pitals using a range of scanner systems. General aspects of MRI, 123I-
FP-CIT-DAT-SPECT, 11C-PiB-PET, and 18F-FDG-PET imaging are sum-
marized in subsection 2.5.1–2.5.5. Imaging details are provided in
Appendix A.
2.5.1. Acquisition of MRI
MRI was performed on a clinical 1.5 or 3.0 Tesla system. A high-
resolution 3D T1 weighted MRI sequence suitable for tissue segmen-
tation was available in 77 subjects. A semi-quantitative CIS ratio ana-
lysis of the high-resolution 3D T1 weighted MRI sequence was per-
formed as describe in subsection 2.5.5.1.
2.5.2. Analysis of 123I-FP-CIT-DAT-SPECT
A visual interpretation of reduced symmetric or asymmetric tracer
uptake in putamen and/or caudate nucleus was defined as abnormal,
supported by the semiquantitative analysis of the specific binding ratio
of striatum, caudate nucleus, and putamen relative to occipital cortex
and the putamen/caudate nucleus uptake ratio [5,22].
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2.5.3. Analysis of 11C-PiB-PET
A visual interpretation of increased tracer uptake in at least two
cortical AD specific regions at the level of or above white matter sup-
ported by cortex-to-cerebellar grey matter uptake ratio > 1.5 was de-
fined as abnormal [28]. An abnormal 11C-PiB-PET was indicated as
Aβ+, whereas a normal 11C-PiB-PET was indicated as Aβ− .
2.5.4. Acquisition of 18F-FDG-PET
The PET imaging was performed according to the international
practice guideline [35]. PET images were acquired using clinical PET/
CT or PET/MRI systems after an intravenous bolus of 200–300 MBq
18F-FDG as a 10 min static scan during the 40–60 min post-injection
time window. All images were reconstructed using CT based attenua-
tion correction [2].
2.5.5. Analysis of 18F-FDG-PET
2.5.5.1. Analysis of quantitative CIS ratio. The high-resolution 3D T1
weighted MRI sequence was segmented using FreeSurfer (version 5.3.0)
[8] to generate region of interests (ROIs) of PCC, precuneus, cuneus,
and cerebellar grey matter for each hemisphere based on the Desikan-
Killiany Atlas. The 18F-FDG-PET image of each patient was fused to the
segmented MRI and the mean ROI values were obtained. Only non-
partial volume corrected PET data was used, as partial volume
corrected by the Symmetric Geometric Transfer Matrix method [12]
was not Please insert hyphen: "suf-< br>ficiently"sufficiently robust.
The mean standardized uptake value (SUV) of each region was
normalized to cerebellum. In each hemisphere the ratio for the mean
SUV in the PCC ROI was divided by the mean SUV in the combined
precuneus plus cuneus ROIs, the quantitative CIS ratio was derived by
averaging the ratios for each hemisphere [21].
2.5.5.2. Standardized reading approach for the visual interpretation. A
clinical standardized reading approach in SyngoVia (SyngoVia, MI
Neurology, Siemens Healthcare, Erlangen, Germany) of the 18F-FDG-
PET scan co-registered to the structural scan (i.e. low-dose CT, non-
enhanced diagnostic CT or MRI) was performed.
The visual interpretation of the 18F-FDG-PET scan was performed in
the following order: First, scoring of the visual CIS scale, then rating of
occipital hypometabolism, and finally assessment of the forced diag-
nosis. Rating of CIS was based on visual evaluation only, whereas
evaluation of occipital hypometabolism and forced diagnosis was sup-
ported by the statistical surface projections from a normal database
supplied by the software vendor (age 46–75 years) using cerebellum as
a reference region.
Two experienced nuclear medicine physicians (IL and OMH)
blinded to all clinical data visually assessed all the 18F-FDG-PET scans.
In case of disagreement a consensus evaluation was performed between
the two readers.
2.5.5.3. Development of the visual CIS-scale. To define the degree of CIS
for the visual scale, we evaluated 18F-FDG-PET images from five DLB
patients and ten AD patients with a wide range of CIS presentations.
Based on the evaluations of the 18F-FDG-PET images, the visual CIS
scale was developed and adjusted to the final version by two
experienced nuclear medicine physicians (IL and OMH).
2.5.5.4. Standardized reading approach for the visual CIS-scale. A
standard reading approach was used to standardize the 18F-FDG-PET
images and optimize the visualization of the CIS region (Fig. 1):
• the 18F-FDG-PET scan was displayed on a clinical workstation using
SyngoVia with the PET image superimposed on the structural scan.• the scan was displayed in “PET Rainbow” and windowing adjusted
to basal ganglia red and cerebellum green/yellow with red hues.• three-way orthogonal view approximately along AC-PC plane with
both sagittal and axial planes through PCC, precuneus, and cuneus.
The visual CIS scoring was based on both sagittal and axial views.
2.5.5.5. Scoring of the visual CIS scale. First, the degree of
hypometabolism in PCC, precuneus, and cuneus was classified for
each hemisphere as “none”, “mild”, or “moderate-to-severe”.
Secondly, the presence of CIS was based on the degree of hypo-
metabolism in PCC, precuneus, and cuneus together with a visual, in-
terpretation of CIS including influence of central or cortical atrophy,
and rated for each hemisphere according to the following criteria:
0 = absent (PCC similar or lower than precuneus and cuneus).
1 = intermediate (e.g. PCC hypometabolic, but less than precuneus
and cuneus, or only precuneus lower than PCC).
2 = present (typically PCC normal and both precuneus and cuneus
lower).
If the activity uptake in precuneus or cuneus was considered re-
duced because of adjacent leukoaraiosis or ischemia on the available
structural scan the rating was changed to 0.
Finally, the ratings from each hemisphere were summed to a visual
CIS score. Three examples of scorings of the visual CIS scale are giving
in Fig. 2.
For clinical operationalization the visual CIS score was classified as:
Score 0 = “no CIS”.
Score 1–2 = “possible CIS”.
Score 3–4 = “definite CIS”.
2.5.5.6. Occipital hypometabolism. Occipital hypometabolism was
assessed in lateral and medial occipital cortices and rated as
“present” or “absent”.
2.5.5.7. Forced diagnosis. This approach was adopted to mimic the
usual reading approach of a nuclear medicine physician. The forced
diagnosis was based on the overall visual interpretation of the 18F-FDG-
PET scan including typical features of DLB (predominant occipital
involvement with no or minimal involvement of frontal or anterior
temporal cortex) and typical features of AD (anterior temporal, mesial
temporal, or AD like parietotemporal hypometabolism with occipital
sparing). The readers were asked to give a forced diagnosis of the most
likely aetiology (“DLB”, “AD”, “other abnormal”, or “normal”).
2.6. Statistical analysis
Differences between groups were assessed with Kruskal-Wallis tests
followed by Mann-Whitney post-hoc tests or one-way ANOVA tests
followed by Tukey post-hoc tests for continuous variables, and
Pearson's or Fischer's Chi-square test for count variables, where ap-
propriate.
The interrater agreement was quantified by Cohen's weighted
Kappa. The Spearman's correlation analysis was applied for comparing
the quantitative CIS ratio values and the visual CIS scores, and for
verifying the correlations between visual CIS score, MMSE score, age,
education, and symptom duration for all subjects and DLB patients. For
the latter, the Spearman correlation results were corrected by false
discovery rate (FDR) correction. The diagnostic accuracy for each
binary disease group comparison was reported as sensitivity, specifi-
city, balanced accuracy, and area under the receiver-operator char-
acteristic curve (AUC). Balanced accuracy is defined as the average of
sensitivity and specificity for the cut-off score, and compensates for the
imbalanced number in the disease groups [4].
The optimal cut-off was established by maximizing the Youden
index. Youden index is defined as the sum of sensitivity and specificity
minus one [39].
Statistical analysis was performed using SAS Studio software, ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 8.0.0
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for Windows (GraphPad Software, San Diego, California USA). A two-
sided p-value< .05 was considered indicative of statistical significance.
3. Results
3.1. Baseline characteristics
Two patients with a clinical diagnosis of DLB and one patient with a
clinical diagnosis of AD were excluded during the visual assessment of
the 18F-FDG-PET scans due to poor quality. The flow diagram of the
study population is shown in (Appendix B, Fig. B.1). Demographics are
shown in Table 1. There were no significant differences in the baseline
demographics between the two dementia groups (DLB patients and AD
patients) or the DLB subgroups (DLB Aβ− patients and DLB Aβ+ pa-
tients). The controls had a significantly higher MMSE score than all
dementia groups (AD, DLB Aβ− patients and DLB Aβ+ patients) and
Fig. 1. Standardized reading approach of 18F-FDG-PET.
Abbreviations: MRI = magnetic resonance imaging; PCC = posterior cingulate cortex; 18F-FDG-PET = 18F-fluoro-deoxy-glucose positron emission tomography;
MRI and 18F-FDG-PET image displayed in saggital and axial plane in Scenium with orientation through PCC (green), precuneus (yellow) and cuneus (red).
Fig. 2. 18F-FDG-PET images with examples of the visual CIS-score and quantitative CIS ratio.
Abbreviations: Aβ = amyloid beta; AD = Alzheimer's disease; CIS = cingulate island sign; DLB = dementia with Lewy bodies; L = left; MMSE = Mini-Mental State
Examination; PCC = posterior cingulate cortex; R = right; 18F-FDG-PET = 18F-fluoro-deoxy-glucose positron emission tomography; Axial and sagittal view of the
PET image superimposed on the high-resolution 3D T1 weighted MRI sequence (top) and the statistical surface (right lateral, left lateral, anterior, and posterior view)
projections using cerebellum as a reference region compared to a healthy age-matched control group (bottom).
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longer education in years compared to DLB patients.
3.2. Reliability of the visual CIS scale
According to Cohen's weighted kappa, the interrater agreement of
the visual CIS score between the two readers was 0.73 (95% CI
0.63;0.83). The two readers had disagreement of the visual CIS scores in
26 of 97 cases, of which 61% was of one grade, 35% was of two grades,
4% (1 case) was of three grades. The distribution of the visual CIS
scores between the two readers are shown in Appendix C, Table C.1.
The quantitative CIS ratio analysis was performed in the 77 subjects
with a high-resolution 3D T1 weighted MRI sequence. The correlation
of the visual CIS score with the quantitative CIS ratio value was mod-
erate-to-strong (Spearman's correlation coefficient, r = 0.60, 95% CI
0.44–0.73; p < .0001) (Fig. 3).
3.3. DLB patients and AD patients
Table 2 shows that the median visual CIS score was significantly
higher for DLB patients in comparison to AD patients, and controls. In
line with this, the mean quantitative CIS ratio was significantly higher
for DLB patients compared to AD patients and controls. Most of the AD
patients (75%) and controls (87%) were evaluated to have “no CIS”
based on the classification of the visual CIS score in comparison to a
minority of the DLB patients (26%).
An optimal cut-off score on the visual CIS scale of ≥2 had a sen-
sitivity of 51% and a specificity of 92% in differentiating DLB patients
and AD patients, yielding a balanced accuracy of 72% (Table 3). In
comparison, the optimal cut-off value of ≥0.98 on the quantitative CIS
ratio separated DLB patients and AD patients with a higher sensitivity of
88% and a lower specificity of 67%, yielding a balanced accuracy of
77%. When comparing the performance of the two methods by an AUC
analysis, we observed no significant difference (p = .45) in differ-
entiating DLB patients and AD patients, although the latter method had
a slightly better performance. Also, the visual CIS scale did not differ in
performance when compared with visual interpretation of occipital
hypometabolism and forced diagnosis for distinguishing DLB patients
and AD patients (Table 3).
3.4. Amyloid positive and amyloid negative DLB patients
The DLB Aβ− patients had the highest median visual CIS score of 4,
followed by DLB Aβ+ patients with a median score of 1, and lastly the
AD patients with a median score of 0. However, the visual CIS score
were only significant different between the AD patients and the DLB
subgroups, although the difference between DLB Aβ+ patients and DLB
Aβ− patients reached a trend level of p = .06. A significant larger
proportion of the DLB Aβ− patients (58%) was classified with “definite
CIS”, when compared both to DLB Aβ+ patients (25%) and to AD
patients (3%) (Table 2).
As shown in Table 3, an optimal cut-off score of 4 on the visual CIS
scale distinguish DLB Aβ− patients from the DLB Aβ+ patients and AD
patients with a balanced accuracy of 70% and 80% respectively. When
applying the Fishers exact test, the proportion of DLB Aβ− patients
with a visual CIS score 4 was significantly higher compared to the DLB
Aβ+ patients and AD patients. Whereas, the proportion of DLB
Aβ+ patients with an optimal cut-off score ≥1 was significantly higher
than the AD patients.
No significant differences were observed between the visual CIS
scale and the quantitative CIS ratio for separating the diagnostic groups.
3.5. Clinical correlations
Box plot of MMSE scores across CIS scores (Appendix D, Fig. D.1)
and Kruskal-Wallis test (p = .55) did not indicate an association of
MMSE with visual CIS score.
Furthermore, the pairwise correlations between the visual CIS score
and MMSE score, age, education, and symptom duration for all subjects
and DLB patients were investigated with a Spearman correlation ana-
lysis both for all subjects and for DLB patients (Appendix D, Table D.1
and D.2). The visual CIS score was not significant correlated with any
clinical variable, neither for all subjects or for DLB patients.
Table 1
Baseline demographics.
AD Controls DLB DLB Aβ− DLB Aβ+
Subjects, n 36 23 35 19 16
Female, n (%) 11 (30.6%) 8 (34.8%) 10 (28.6%) 4 (21.0%) 6 (37.5%)
Age, mean years± SD 70.6 ± 6.3 68.7 ± 6.1 69.9 ± 6.8 68.0 ± 8.3 72.1 ± 3.5⁎
MMSE, mean score ± SD 25.8 ± 2.9⁎ 29.3 ± 1.2 26.3 ± 3.2⁎ 26.1 ± 3.3⁎ 26.6 ± 3.1⁎
Education, mean years± SD 13.5 ± 2.8 14.5 ± 2.4 12.8 ± 2.8⁎ 13.0 ± 2.7 12.6 ± 3.0
Symptom duration, mean years± SD 3.1 ± 3.1 NA 2.9 ± 2.8 2.3 ± 2.2 3.6 ± 3.4
Abbreviations: Aβ = amyloid beta; AD = Alzheimer's disease; DLB = dementia with Lewy bodies; MMSE =Mini-Mental State Examination; n = number; NA = not
applicable; SD = standard deviation;
⁎ Differ significantly from Controls (p < .05).
0 1 2 3 4
0.6
0.8
1.0
1.2
1.4
The visual CIS score
T
he
qu
an
tit
at
iv
e
C
IS
-r
at
io
va
lu
e
Fig. 3. Correlation of the visual CIS score and the quantitative CIS ratio value.
Abbreviations: CIS = cingulate island sign; Boxplot graph with the boxes cor-
responding to median values with indications of the 25th and 75th percentiles,
and the whiskers show the minimum and maximum values. The+ indicates the
mean. All the subjects are plotted as ○. The Spearman's correlation coefficient
of all five groups on the visual CIS score (0, 1, 2, 3, and 4) and the quantitative
CIS ratio was r = 0.60 (95% CI 0.44–0.73, p < .0001).
L. Gjerum, et al. Journal of the Neurological Sciences 410 (2020) 116645
5
4. Discussion
CIS is a supportive marker of DLB on 18F-FDG-PET, and is useful in
the discrimination of DLB from AD [26], however, a visual rating scale
for CIS has been lacking. With this study we aimed to develop a robust
visual rating scale from clinically acquired 18F-FDG-PET scans to detect
the degree of CIS. We found an acceptable interrater agreement with
most disagreements amounting to a single grade in the low-grade
group, and a moderate-to-strong correlation with the quantitative CIS
ratio, suggesting that the visual CIS scale is useful in a clinical setting as
an aid in assessment of CIS.
Furthermore, we found significant differences between the groups
median visual CIS scores in both the diagnostic groups analysis (DLB,
AD, and controls) and the subgroups analysis (DLB Aβ−, DLB Aβ+,
and AD). Notably, a cut-off visual CIS score of 4 could significantly
differentiate the DLB Aβ− patients from the DLB Aβ+ patients, which
reflects that the degree of CIS may be associated with Aβ pathology in
DLB patients.
The original study introducing visual interpretation of CIS for dif-
ferentiating DLB from AD by Lim et al. found CIS to be highly specific
for DLB with a specificity of 100% and a sensitivity ranging from 62%
to 86% [21]. The higher diagnostic accuracy in the prior study
compared to our findings may be due to a restricted dichotomized
rating of CIS in a relatively small study cohort of 14 DLB patients and
10 AD patients, together with only 29% of DLB patients having AD
pathology. In contrast, we aimed to characterize the degree of CIS in the
pathological heterogenous DLB patients considering previous studies
have demonstrated higher CIS ratio in DLB patients compared to AD
patients [11,15,19,21,31] together with over half of pathologically
confirmed DLB cases have coexisting AD pathology [3,10].
We evaluated the performance of the visual CIS scale against a
quantitative CIS method as the presence of CIS has mainly been de-
monstrated by various quantitative methods [11,15,19,21,31,38]. In
accordance with the previous studies, we found a significantly higher
quantitative CIS ratio for the DLB patients compared to the AD patients
and controls (Table 2). The visual CIS scale had a similar diagnostic
accuracy compared to the quantitative CIS ratio in distinguishing DLB
patients from AD patients, but from a clinical perspective a visual rating
scale is advantageous compared to a quantitative method for several
reasons. A quantitative method can be time consuming, the actual value
depends on both the acquisition and processing of the 18F-FDG-PET
and MRI, and the specific software used may only be accessible in ex-
pert centres. A cut-off value may thus only be applicable to a specific
setup in a single centre. In contrast, a visual rating scale for CIS can be
implemented as a fast-diagnostic adjunct to the standard visual 18F-
FDG-PET scan evaluation without additional software.
The visual CIS scale was also compared to another relevant 18F-
FDG-PET feature (occipital hypometabolism) and to an overall visual
evaluation of the 18F-FDG-PET image including typical and atypical
features of DLB and AD (forced diagnosis). The performance for these
18F-FDG-PET visual features in distinguishing DLB from AD were
consistent with two previous studies of similar ratings [21,31], and
comparable to the visual CIS scale. This suggests that the visual CIS
scale may supplement or even replace more resource demanding
techniques performed by experienced nuclear medicine physicians.
Finally, we examined if the presence of CIS was influenced by
concurrent Aβ pathology in DLB patients. Comparable to previous
studies [7,20], we found that nearly half (46%) of the patient with a
clinical diagnosis of DLB had an abnormal Aβ biomarker (Aβ+). Two
previous studies consisting of a smaller study of 10 DLB patients [17]
Table 2
The visual CIS scale and the quantitative CIS ratio.
AD Controls DLB DLB Aβ− DLB Aβ+
Subjects, n 36 23 35 19 16
Visual CIS score
0/1/2/3/4, n 27/6/2/0/1 20/1/2/0/0 12/5/3/1/14 5/2/0/1/11 7/3/2/1/3
Median score (IQR) 0 (0.5) 0 (0) 2 (4)⁎ 4 (4)⁎,‡ 1 (2.5)⁎
Visual CIS classification
No CIS/Possible CIS/Definite CIS, n 27/8/1 20/3/0 12/8/15⁎ 5/3/11⁎ 7/5/4⁎
Quantitative CIS ratio
Mean value± SD 0.98 ± 0.08 0.96 ± 0.07 1.09 ± 0.10⁎ 1.11 ± 0.10⁎ 1.05 ± 0.09
Abbreviations: Aβ = amyloid beta; AD = Alzheimer's disease; CIS = cingulate island sign; DLB = dementia with Lewy bodies; IQR = interquartile range;
n = number; SD = standard deviation;
⁎ Differ significantly from AD and controls (p < .05).
‡ Trend difference from DLB Aβ + (p = .06).
Table 3
Diagnostic accuracy of the visual CIS scale, quantitative CIS ratio and 18F-FDG-
PET visual features.
DLB versus AD
Sens. Spec. Bal. acc. AUC (95% CI)
Visual CIS score ≥2 51.4% 91.7% 71.6% 0.77 (0.64–0.89)
Quantitative CIS ratio value
≥0.98
87.5% 66.7% 77.1% 0.82 (0.70–0.94)
Occipital hypometabolism 54.3% 91.7% 73.0% 0.74 (0.63–0.85)
Forced diagnosis 51.4% 94.4% 72.9% 0.78 (0.66–0.90)
DLB Aβ− versus AD
Sens. Spec. Bal. acc. AUC (95% CI)
Visual CIS score = 4 63.2% 97.2% 80.2% 0.85 (0.71–0.99)
Quantitative CIS ratio value
≥1.04
85.7% 86.7% 86.2% 0.88 (0.77–0.98)
DLB Aβ+ versus AD
Sens. Spec. Bal. acc. AUC (95% CI)
Visual CIS score ≥1 56.3% 75.0% 65.6% 0.65 (0.45–0.85)
Quantitative CIS ratio value
≥0.99
80.0% 76.7% 78.3% 0.74 (0.54–0.94)
DLB Aβ− versus DLB Aβ+
Sens. Spec. Bal. acc. AUC (95% CI)
Visual CIS score = 4 57.9% 81.3% 69.6% 0.73 (0.52–0.93)
Quantitative CIS ratio value
≥1.04
85.7% 50.0% 67.9% 0.66 (0.43–0.90)
Abbreviations: Aβ = amyloid beta; AD = Alzheimer's disease; AUC = the area
under the receiver operating characteristic curve; Bal. acc. = balanced accu-
racy; CI = confidence interval; CIS = cingulate island sign; DLB = dementia
with Lewy bodies; Sens. = sensitivity; Spec. = specificity; 18F-FDG-
PET = 18F-fluoro-deoxy-glucose positron emission tomography.
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and a larger study of 39 DLB patients [11] with determination of the
brain Aβ status by 11C-PiB-PET found no association between a quan-
titative method of CIS and Aβ accumulation. Likewise, we found no
significant differences between the DLB Aβ− patients and DLB
Aβ+ patients for the quantitative CIS ratio. However, we found that the
DLB Aβ− patients had the highest score on the visual CIS scale in
comparison to the DLB Aβ+ patients with intermediate values
(Table 2) as an indication of coexisting Aβ pathology may diminish the
presence of CIS, although the difference only reached a trend level of
p = .06.
Additionally, a cut-off visual CIS score of 4 discriminated the DLB
Aβ− patients from DLB Aβ+ patients with a balanced accuracy of
70%, and this finding corroborate that Aβ pathology might be a pos-
sible confounding factor associated with the presence of CIS in DLB
patients, which is relevant to include in the interpretation of CIS.
In general, the visual CIS scale distinguishes the diagnostic groups
(DLB and AD) and the subgroups (DLB Aβ−, DLB Aβ+, and AD) with
high specificities, but only moderate sensitivities. This may be ex-
plained by various potentially confounding circumstances. Previous
studies have suggested that CIS may be influenced by the severity of
cognitive impairment [11,30], however, in line with a previous study
[15], we did not find a relationship between CIS and MMSE. The
implementation of the visual CIS scale in a routine practice is poten-
tially valuable considering that visual features including cingulate hy-
pometabolism seemed to be underreported and missed on the clinical
interpretation of FDG-PET scans of patients with DLB [13].
Combining the visual CIS scale on 18F-FDG-PET with visual as-
sessment of atrophy pattern on MRI [32] could potentially increase the
accuracy of DLB diagnosis and could be explored in future studies.
Furthermore, the visual CIS scale should preferably be evaluated in a
larger mixed memory cohort with unknown diagnosis and by less ex-
perienced readers.
Some limitations should be considered. In this study, the diagnosis
of DLB and AD lacked pathological confirmation, but the reference
diagnosis was based on reconfirmed diagnosis by an experienced de-
mentia specialist (SGH, AH, and PH) according to the current DLB
diagnostic criteria [25] and AD research criteria [27], and based on all
available data including clinical follow up for at least 12 months for the
majority of the patients.
Another limitation is the selection criteria, considering that we only
included DLB patients with an Aβ biomarker and a 123I-FP-CIT-DAT-
SPECT and AD patients with an Aβ biomarker, respectively, which are
considered as supplementary disease biomarkers if the diagnosis is
questionable in our clinics. Consequently, our study population may
consist of patients with a more heterogenous clinical presentation,
which may diminish the diagnostic accuracy. A final limitation is the
use of different scanners given that the diagnostic workup for the study
population was performed across several centres. On the other hand,
visual ratings are in general more robust for scanner differences and
should be applicable without consideration of the scanner.
Among the strengths of this study is the relatively large sample size
with a comprehensive diagnostic evaluation program together with
explicitly including DLB patients with an abnormal 123I-FP-CIT-DAT-
SPECT. The latter is an indicative biomarker of DLB [26].
In conclusion, our study demonstrated that the visual CIS scale was
robust and clinical applicable to evaluate the presence of CIS, which
may help to improve the accuracy of clinical diagnosis of DLB.
Furthermore, the degree of CIS may be associated with the presence of
Aβ pathology in DLB patients. In perspective, the validity of the visual
CIS scale should be evaluated in a larger mixed memory cohort and by
less experienced readers.
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Appendix A
A.1. Imaging details
A.1.1. MRI
MRI were acquired using a 1.5 Tesla GE Medical (Optima MR450w, Signa Hde, or Signa HDxt) (n= 19), 1.5 or 3 Tesla Philips (Achieva) (n= 4),
or 1.5 or 3 Tesla Siemens (Aera, Avanto, Biograph, Espree, Trio, or Verio) (n = 74)
A.1.2. 123I-FP-CIT-DAT-SPECT
The DAT-SPECT imaging was performed according to the international practice guideline [5]. DAT-SPECT images were acquired using Triple-
head IRIX camera (Philips Medical) (n = 27), PRISM 3000XP (Marconi, Philips) (n = 5), or Infina Hawkeye (GE) or Syngo Symbia T2 (Siemens)
(n = 4)
In general, the SPECT image was acquired on either brain dedicated SPECT or general SPECT/CT systems 180–240 min after an intravenous bolus
of 200 MBq 123I-FP-CIT.
A.1.3. 11C-PiB-PET
The PET imaging was performed according to the international practice guideline [28]. PET images were acquired using a Siemens Biograph mCT
PET/CT scanner (Siemens Healthcare, Erlangen, Germany) (n = 15). In general, a 20–30 min static PET acquisition was performed on a standard
PET/CT system 40 min after an intravenous bolus of 150–400 MBq 11C-PiB. After spatial normalization, images were analysed using clinical
workstations, SyngoVia (SyngoVia, MI Neurology, Siemens Healthcare, Erlangen, Germany). The activity uptake in AD specific ROIs was defined [9],
and uptake values calculated relative to cerebellar grey matter. The uptake was assessed after co-registration to the structural scan
A.1.4. 18F-FDG-PET
Imaging details are summarized in Table A.1
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Table A.1
Imaging details for 18F-FDG-PET.
Subjects (n) Scanner Reconstruction method Matrix size
2 GE Medical (Discovery MI) QCFX or VPFXS 256 × 256
6 Philips (Gemini) LOR-RAMLA or 3D-RAMLA 128 × 128
89 Siemens (Biograph mCT, Biograph mMR, or Somatom, 1094) OSEM 336 × 336, 344 × 344, or 400 × 400
Abbreviations: n = numbers; 18F-FDG-PET = 18F-fluoro-deoxy-glucose positron emission tomography.
Appendix B
Fig. B.1. Flow diagram of the study population
Retrospective cohort study design and study flow diagram.
Appendix C
Table C.1
Distribution of the visual CIS scores between the two readers.
Visual CIS score Reader 1 Total
0 1 2 3 4
Reader 2 0 49 2 3 0 0 54
1 5 3 2 0 1 11
2 2 0 5 0 0 7
3 0 3 4 0 3 10
4 0 0 1 0 11 12
Total 56 8 15 0 15 94
Abbreviations: CIS = cingulate island sign.
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Appendix D
Fig. D.1. Boxplot for visual CIS score and MMSE score.
Abbreviations: CIS = cingulate island sign; MMSE = mini-mental state examination. Boxplot graph with the boxes corresponding to median values with indications
of the 25th and 75th percentiles, and the whiskers show the minimum and maximum values. The + indicates the mean. All the subjects are plotted as ○.
Overall comparison of all five groups on the visual CIS score (0, 1, 2, 3, and 4) and MMSE score with the Kruskal-Wallis tests (p = .55).
Table D.1
Correlation analysis between visual CIS score, MMSE score, age, education, and symptom duration for all subjects.
Correlation coefficient (r) Visual CIS score MMSE, score Age, years Education, years Symptom duration, years
Visual CIS score 1.0 −0.08 −0.007 −0.11 0.12
MMSE, score −0.08 1.0 −0.18 0.26⁎ −0.32⁎
Age, years −0.007 −0.18 1.0 −0.06 −0.04
Education, years −0.11 0.26⁎ −0.06 1.0 −0.26⁎
Abbreviations: CIS = cingulate island sign; FDG = false discovery rate; MMSE = Mini-Mental State Examination.
⁎ p < .05 (FDR corrected).
Table D.2
Correlation analysis between visual CIS score, MMSE score, age, education, and symptom duration for DLB group.
Correlation coefficient (r) Visual CIS score MMSE, score Age, years Education, years Symptom duration, years
Visual CIS score 1.0 0.21 0.02 0.13 −0.10
MMSE, score 0.21 1.0 −0.17 0.12 −0.02
Age, years 0.02 −0.17 1.0 −0.31 0.07
Education, years 0.13 0.12 −0.31 1.0 −0.15
Abbreviations: CIS = cingulate island sign; MMSE = Mini-Mental State Examination.
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